These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31650026)

  • 1. Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.
    Ying Z; He T; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Qi F; Ding Y; Lu XA; Song Y; Zhu J
    Mol Ther Oncolytics; 2019 Dec; 15():60-68. PubMed ID: 31650026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics.
    Zhong Q; Zhu YM; Zheng LL; Shen HJ; Ou RM; Liu Z; She YL; Chen R; Li C; Huang J; Yao MD; Zhang Q; Liu S
    Acta Haematol; 2018; 140(3):131-140. PubMed ID: 30253384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia.
    Zhao X; Yang J; Zhang X; Lu XA; Xiong M; Zhang J; Zhou X; Qi F; He T; Ding Y; Hu X; De Smet F; Lu P; Huang X
    Mol Ther Oncolytics; 2020 Sep; 18():272-281. PubMed ID: 32728615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
    Ying Z; He T; Jin S; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Liu W; Deng L; Ding Y; Hu X; Bu B; Lu X; Song Y; Zhu J
    Chin J Cancer Res; 2022 Feb; 34(1):53-62. PubMed ID: 35355931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.
    Wu L; Chen J; Cai R; Wang X; Liu Y; Zheng Q; Li L
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
    Onea AS; Jazirehi AR
    Am J Cancer Res; 2016; 6(2):403-24. PubMed ID: 27186412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
    Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
    Zhang Y; Li J; Lou X; Chen X; Yu Z; Kang L; Chen J; Zhou J; Zong X; Yang Z; Li M; Xu N; Jia S; Geng H; Chen G; Dai H; Tang X; Yu L; Wu D; Li C
    Front Oncol; 2021; 11():664421. PubMed ID: 34113569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
    Kouro T; Higashijima N; Horaguchi S; Mano Y; Kasajima R; Xiang H; Fujimoto Y; Kishi H; Hamana H; Hoshino D; Himuro H; Matsuura R; Tsuji S; Imai K; Sasada T
    Int J Cancer; 2024 May; 154(10):1828-1841. PubMed ID: 38212893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
    Cao Y; Lu W; Sun R; Jin X; Cheng L; He X; Wang L; Yuan T; Lyu C; Zhao M
    Front Oncol; 2019; 9():767. PubMed ID: 31482064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of CRISPR-based non-viral
    Hu Y; Zu C; Zhang M; Wei G; Li W; Fu S; Hong R; Zhou L; Wu W; Cui J; Wang D; Du B; Liu M; Zhang J; Huang H
    EClinicalMedicine; 2023 Jun; 60():102010. PubMed ID: 37251628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.
    Bove C; Arcangeli S; Falcone L; Camisa B; El Khoury R; Greco B; De Lucia A; Bergamini A; Bondanza A; Ciceri F; Bonini C; Casucci M
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
    Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
    Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.
    Yang C; Lei W; Xie H; Wu G; Wei J; Liang A; Qian W
    Onco Targets Ther; 2020; 13():12163-12168. PubMed ID: 33268994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis.
    Al-Mansour M; Al-Foheidi M; Ibrahim E
    Mol Clin Oncol; 2020 Oct; 13(4):33. PubMed ID: 32789017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.